Neovascular glaucoma is a sight-threatening condition, and can rapidly progress from rubeosis with normal intraocular pressure (IOP), to secondary open-angle glaucoma with raised IOP and finally secondary angle-closure glaucoma with uncontrolled IOP. Early detection and aggressive management with panretinal photocoagulation, intravitreal anti-vascular endothelial growth factor (VEGF), topical aqueous suppressants and valved glaucoma drainage surgery can reduce risk of significant visual loss secondary to neovascular glaucoma. This editorial explores some simple measures that can increase surgical success rates and minimise complications.
Rubeotic or neovascular glaucoma is an aggressive secondary glaucoma, which if untreated, rapidly progresses to permanent and devastating visual loss. First described in 1871, it has also been labelled as haemorrhagic glaucoma, thrombotic glaucoma or congestive glaucoma. It results from neovascularisation of the iris and angle structures as a result of severe, diffuse and chronic retinal ischaemia.
The underlying aetiology could be any one from a list of over 20 different potential causes, 1 with central retinal vein occlusion, proliferative diabetic retinopathy and ocular ischaemic syndrome following carotid artery obstruction accounting for over 80%. 2 Neovascular glaucoma has historically been associated with a very poor prognosis, largely because patients present with established secondary angle-closure glaucoma and significantly reduced vision.
Such advanced disease is often refractory to medical and laser treatments. Early diagnosis and aggressive treatment is therefore key to obtaining favourable outcomes.
Practical assessment of patients with neovascular glaucoma or suspected neovascular glaucoma involves careful undilated examination of the iris, and gonioscopy using a high-magnification lens such as Ocular Magna View Gonio (Ocular Instruments Inc., Bellevue, WA, US) is essential to detect early angle neovascularisation, assessment of aqueous flare, and should be followed by retinal examination to determine the underlying pathology. Although neovascularisation usually progresses from the pupil margin towards the angle, angle neovascularisation can sometimes precede iris neovascularisation, especially when due to central retinal vein occlusion. 3 Iris fluorescein angiography can be used to detect rubeosis prior to it being clinical evident on slit lamp biomicroscopy. 4 Assessment of visual potential is also key to directing management options. EUROPEAN OPHTHALMIC REVIEW compared to 400-650 spots. 5 Difficulties may arise in performing PRP due to corneal oedema (from raised IOP), vitreous haemorrhage or hyphaema, or co-existing dense cataract, which may need treatment prior to undertaking PRP.
Intravitreal anti-vascular endothelial growth factor (VEGF) injection has been clearly shown to have an effective adjunctive affect to PRP and reduce further progression. 6 It can produce rapid regression of iris neovascularisation, 7 as the onset of action is much faster than PRP, and can also help control IOP in the secondary open-angle glaucoma stage. Even if secondary closed-angle glaucoma has been established, it may be useful prior to surgery to reduce intra-operative haemorrhage and improve surgical success rates. 8 VEGF levels in the aqueous humour of patients with neovascular glaucoma are known to be 15-20 times that of normal eyes. 9 Intravitreal anti-VEGF is therefore recommended for all stages of neovascular glaucoma. Caution should, however, be taken in cases of ocular ischaemic syndrome as one study observed central retinal artery occlusion in 50% of patients following intravitreal bevacizumab. Cataract progression is usually rapid in this group of patients who will almost all require cataract surgery at some stage. We would therefore strongly recommend valve surgery combined with cataract extraction and intraocular lens implant at the same time.
Table 1: Clinical experiences
Tips for successful diagnosis of neovascular glaucoma:
• Perform careful undilated examination of the iris and gonioscopy to assess the extent of neovascularisation In cases of very poor visual potential, the aim of treatment is to control pain, which usually arises from the uncontrolled IOP and subsequent corneal oedema. Cyclodestructive procedures such as transcleral cyclophotocoagulation is successful in achieving symptom control in combination with topical steroids and cycloplegia, albeit with risk of hypotony and phthisis. 12 Additional intravitreal anti-VEGF has also been shown to be a useful adjunct in producing rapid pain relief in refractory neovascular glaucoma. 13 Long-term outcomes and the prognosis of eyes treated with the latest approaches in the management of neovascular glaucoma are lacking from recent literature. However, the addition of intravitreal anti-VEGF has revolutionised the treatment of neovascular glaucoma, and in combination with early detection, thorough pan-retinal photocoagulation and safe surgical intervention should result in long-lasting maintenance of visual functional and acceptable IOP control. ■
